Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!


dexrazoxane (deks-ra-zoks-ane)

Totect, Zinecard


Therapeutic: cardioprotective agents

Pharmacologic: chelating agents


Reduce incidence and severity of cardiomyopathy from doxorubicin in women with metastatic breast cancer who have already received a cumulative dose of doxorubicin >300 mg/m2. Treatment of extravasation resulting from IV anthracycline chemotherapy.


Acts as an intracellular chelating agent. Therapeutic Effects: Diminishes the cardiotoxic effects of doxorubicin. Decreased damage from extravasation of anthracyclines.

Adverse Reactions/Side Effects

Hemat: myelosuppression. Local: pain at injection site.


Examination and Evaluation

  • Monitor signs of cardiomyopathy such as shortness of breath, dizziness, fatigue, fainting, palpitations, and peripheral/abdominal edema due to fluid accumulation. Increased signs may indicate a lack of drug effects in protecting the heart; notify the physician or nursing staff immediately.

  • Monitor IV injection site for pain, swelling, and irritation. Report prolonged or excessive injection-site reactions to the physician.


  • For patients who are medically able to begin exercise, implement appropriate resistive exercises and aerobic training to maintain muscle strength and aerobic capacity during cancer chemotherapy or to help restore function after chemotherapy.

Patient/Client-Related Instruction

  • Because of myelosuppression, advise patient to guard against infection (frequent hand washing, etc.), and to avoid crowds and contact with persons with contagious diseases.


Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism and Excretion: Some metabolism occurs; 42% eliminated in urine.

Half-life: 2.1–2.5 hr.

|Download (.pdf)|Print

TIME/ACTION PROFILE (cardioprotective effect)

IV rapid unknown unknown


Contraindicated in: Any other type of chemotherapy except other anthracyclines (doxorubicin-like agents).

Use Cautiously in: CCr <40 mL/min (dose reduction required); OB: Pregnancy, lactation, or children (safety not established).


Drug-Drug: Myelosuppression may be ↑ by antineoplastics or radiation therapy. Antitumor effects of concurrent combination chemotherapy with fluorouracil and cyclophosphamide may be ↓ by dexrazoxane.



IV (Adults): 10 mg of dexrazoxane/1 mg doxorubicin.

Renal Impairment

IV (Adults): decrease dose by 50%.

Extravasation protection

IV (Adults): 1000 mg/m2 (maximum 2000 mg) given on days 1 and 2, and followed by a dose of 500 mg/m2 (maximum 1000 mg) on day 3.

Renal Impairment

IV (Adults CCr <40 mL/min): decrease ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.